• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.

作者信息

Simões Marcus V, Fernandes Fabio, Marcondes-Braga Fabiana G, Scheinberg Philip, Correia Edileide de Barros, Rohde Luis Eduardo P, Bacal Fernando, Alves Silvia Marinho Martins, Mangini Sandrigo, Biolo Andréia, Beck-da-Silva Luis, Szor Roberta Shcolnik, Marques Junior Wilson, Oliveira Acary Souza Bulle, Cruz Márcia Waddington, Bueno Bruno Vaz Kerges, Hajjar Ludhmila Abrahão, Issa Aurora Felice Castro, Ramires Felix José Alvarez, Coelho Filho Otavio Rizzi, Schmidt André, Pinto Ibraim Masciarelli Francisco, Rochitte Carlos Eduardo, Vieira Marcelo Luiz Campos, Mesquita Cláudio Tinoco, Ramos Celso Dario, Soares-Junior José, Romano Minna Moreira Dias, Mathias Junior Wilson, Garcia Junior Marcelo Iório, Montera Marcelo Westerlund, Melo Marcelo Dantas Tavares de, Silva Sandra Marques E, Garibaldi Pedro Manoel Marques, Alencar Neto Aristóteles Comte de, Lopes Renato Delascio, Ávila Diane Xavier de, Viana Denizar, Saraiva José Francisco Kerr, Canesin Manoel Fernandes, Oliveira Glaucia Maria Moraes de, Mesquita Evandro Tinoco

机构信息

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto - Brasil.

Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil.

出版信息

Arq Bras Cardiol. 2021 Sep;117(3):561-598. doi: 10.36660/abc.20210718.

DOI:10.36660/abc.20210718
PMID:34550244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8462947/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/d1c9aa78e9a1/0066-782X-abc-117-03-0561-gf12-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/bae0ec15fca6/0066-782X-abc-117-03-0561-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/460e58a7ac17/0066-782X-abc-117-03-0561-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/af9d5a1592c4/0066-782X-abc-117-03-0561-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/fef9fda46e2f/0066-782X-abc-117-03-0561-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/a3e68cda16ed/0066-782X-abc-117-03-0561-gf05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/c5349569620c/0066-782X-abc-117-03-0561-gf06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/c7383c05c8c2/0066-782X-abc-117-03-0561-gf07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/fb7e890fd3b1/0066-782X-abc-117-03-0561-gf08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/4892f84c28fc/0066-782X-abc-117-03-0561-gf09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/77e554a80c21/0066-782X-abc-117-03-0561-gf10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/d7e6cbbee02e/0066-782X-abc-117-03-0561-gf11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/f1ab7070ce31/0066-782X-abc-117-03-0561-gf12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/7e155564d7b1/0066-782X-abc-117-03-0561-gf01-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/77860f3b6d08/0066-782X-abc-117-03-0561-gf02-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/f00c2d351ea4/0066-782X-abc-117-03-0561-gf03-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/9caaf39a7a07/0066-782X-abc-117-03-0561-gf04-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/1bfc25bfdeec/0066-782X-abc-117-03-0561-gf05-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/d40bab508d0f/0066-782X-abc-117-03-0561-gf06-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/7b4f14dde03b/0066-782X-abc-117-03-0561-gf07-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/ab812aba9db7/0066-782X-abc-117-03-0561-gf08-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/308989ad496e/0066-782X-abc-117-03-0561-gf09-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/14cfa12a7ed7/0066-782X-abc-117-03-0561-gf10-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/210186a99242/0066-782X-abc-117-03-0561-gf11-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/d1c9aa78e9a1/0066-782X-abc-117-03-0561-gf12-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/bae0ec15fca6/0066-782X-abc-117-03-0561-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/460e58a7ac17/0066-782X-abc-117-03-0561-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/af9d5a1592c4/0066-782X-abc-117-03-0561-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/fef9fda46e2f/0066-782X-abc-117-03-0561-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/a3e68cda16ed/0066-782X-abc-117-03-0561-gf05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/c5349569620c/0066-782X-abc-117-03-0561-gf06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/c7383c05c8c2/0066-782X-abc-117-03-0561-gf07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/fb7e890fd3b1/0066-782X-abc-117-03-0561-gf08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/4892f84c28fc/0066-782X-abc-117-03-0561-gf09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/77e554a80c21/0066-782X-abc-117-03-0561-gf10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/d7e6cbbee02e/0066-782X-abc-117-03-0561-gf11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/f1ab7070ce31/0066-782X-abc-117-03-0561-gf12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/7e155564d7b1/0066-782X-abc-117-03-0561-gf01-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/77860f3b6d08/0066-782X-abc-117-03-0561-gf02-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/f00c2d351ea4/0066-782X-abc-117-03-0561-gf03-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/9caaf39a7a07/0066-782X-abc-117-03-0561-gf04-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/1bfc25bfdeec/0066-782X-abc-117-03-0561-gf05-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/d40bab508d0f/0066-782X-abc-117-03-0561-gf06-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/7b4f14dde03b/0066-782X-abc-117-03-0561-gf07-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/ab812aba9db7/0066-782X-abc-117-03-0561-gf08-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/308989ad496e/0066-782X-abc-117-03-0561-gf09-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/14cfa12a7ed7/0066-782X-abc-117-03-0561-gf10-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/210186a99242/0066-782X-abc-117-03-0561-gf11-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/716f/8462947/d1c9aa78e9a1/0066-782X-abc-117-03-0561-gf12-en.jpg

相似文献

1
Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.《心脏淀粉样变诊断与治疗立场声明 - 2021》
Arq Bras Cardiol. 2021 Sep;117(3):561-598. doi: 10.36660/abc.20210718.
2
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗：欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
3
Progress in diagnosing and managing cardiac amyloidosis.心脏淀粉样变性的诊断和治疗进展。
Cleve Clin J Med. 2019 Jan;86(1):29-37. doi: 10.3949/ccjm.86gr.18004.
4
Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).心脏淀粉样变性的诊断和治疗：德国心脏病学会（DGK）立场声明。
Clin Res Cardiol. 2021 Apr;110(4):479-506. doi: 10.1007/s00392-020-01799-3. Epub 2021 Jan 18.
5
Cardiac resynchronization therapy in a patient with amyloid cardiomyopathy.
Acta Cardiol. 2013 Jun;68(3):335-7. doi: 10.1080/ac.68.3.2983432.
6
[Cardiac amyloidosis: How to recognize them and manage them?].[心脏淀粉样变性：如何识别与管理？]
Presse Med. 2016 Oct;45(10):845-855. doi: 10.1016/j.lpm.2016.07.001. Epub 2016 Aug 1.
7
Recent advances in the diagnosis and management of cardiac amyloidosis.心脏淀粉样变性诊断与管理的最新进展
Future Cardiol. 2014 Jan;10(1):131-46. doi: 10.2217/fca.13.85.
8
Cardiac amyloidosis: an approach to diagnosis and management.心脏淀粉样变性：诊断与管理方法
Expert Rev Cardiovasc Ther. 2010 Jul;8(7):1007-13. doi: 10.1586/erc.10.41.
9
[Progress in the diagnosis and treatment of cardiac amyloidosis].[心脏淀粉样变性的诊断与治疗进展]
Przegl Lek. 2014;71(6):340-5.
10
Diagnosis and management of the cardiac amyloidoses.心脏淀粉样变的诊断与管理
Circulation. 2005 Sep 27;112(13):2047-60. doi: 10.1161/CIRCULATIONAHA.104.489187.

引用本文的文献

1
Anxiety and depression in cardiac amyloidosis: a systematic review.心脏淀粉样变性中的焦虑和抑郁：一项系统综述。
BMJ Open. 2025 Jul 11;15(7):e094614. doi: 10.1136/bmjopen-2024-094614.
2
Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis.在转甲状腺素蛋白淀粉样变性心肌病3期APOLLO - B研究的巴西亚组人群中进行的帕替西兰治疗：事后分析。
Arq Bras Cardiol. 2025 Mar;122(4):e20240568. doi: 10.36660/abc.20240568.
3
The Complex Puzzle of Hypertrophic Phenotype: A Practical Approach for the Clinician.

本文引用的文献

1
Incorporation of drugs for rare diseases in Brazil: is it possible to have full access to these patients?将罕见病药物纳入巴西医保体系：这些患者能否全面获得这些药物？
Cien Saude Colet. 2021 Nov;26(11):5547-5560. doi: 10.1590/1413-812320212611.26722020. Epub 2020 Jul 29.
2
Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).心脏淀粉样变性的诊断和治疗：德国心脏病学会（DGK）立场声明。
Clin Res Cardiol. 2021 Apr;110(4):479-506. doi: 10.1007/s00392-020-01799-3. Epub 2021 Jan 18.
3
Management of AL amyloidosis in 2020.
肥厚型表型的复杂谜题：临床医生的实用方法
Arq Bras Cardiol. 2025 Mar;122(1):e20240529. doi: 10.36660/abc.20240529.
4
Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.心脏淀粉样变性的超声心动图诊断与管理的进展及挑战
Int J Cardiovasc Imaging. 2025 Feb 26. doi: 10.1007/s10554-025-03362-5.
5
Different Gut Microbiome Profiles in Patients with Transthyretin Amyloidosis with and Without Cardiac Involvement.转甲状腺素蛋白淀粉样变性伴或不伴心脏受累患者的不同肠道微生物群特征
Int J Mol Sci. 2025 Feb 16;26(4):1689. doi: 10.3390/ijms26041689.
6
Cardiovascular Computed Tomography and Magnetic Resonance Imaging Guideline of the Brazilian Society of Cardiology and the Brazilian College of Radiology - 2024.巴西心脏病学会和巴西放射学会心血管计算机断层扫描与磁共振成像指南 - 2024年
Arq Bras Cardiol. 2024 Oct 28;121(9):e20240608. doi: 10.36660/abc.20240608.
7
Diagnostic and therapeutic challenges in rapidly progressing cardiac amyloidosis: a literature review based on case report.快速进展性心脏淀粉样变性的诊断与治疗挑战：基于病例报告的文献综述
Int J Emerg Med. 2024 Oct 21;17(1):159. doi: 10.1186/s12245-024-00750-x.
8
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.肥厚型心肌病诊断与治疗指南 - 2024
Arq Bras Cardiol. 2024 Jul 26;121(7):e202400415. doi: 10.36660/abc.20240415.
9
Unraveling the Challenges in Diagnosing Cardiac Amyloidosis.解析心脏淀粉样变性诊断中的挑战
Arq Bras Cardiol. 2024 May 20;121(4):e20240107. doi: 10.36660/abc.20240107. eCollection 2024.
10
Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning model.利用机器学习模型评估巴西公共卫生系统中的潜在转甲状腺素蛋白淀粉样心肌病病例。
PLoS One. 2024 Feb 15;19(2):e0278738. doi: 10.1371/journal.pone.0278738. eCollection 2024.
2020 年 AL 淀粉样变性的治疗。
Blood. 2020 Dec 3;136(23):2620-2627. doi: 10.1182/blood.2020006913.
4
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病患者用 patisiran 的长期安全性和疗效：一项开放标签扩展研究的 12 个月结果。
Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16.
5
Concomitant Cardiac Amyloidosis in Severe Aortic Stenosis: The Trojan Horse?重度主动脉瓣狭窄合并心脏淀粉样变性：特洛伊木马？
J Am Coll Cardiol. 2021 Jan 19;77(2):140-143. doi: 10.1016/j.jacc.2020.11.007. Epub 2020 Nov 9.
6
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.在转甲状腺素蛋白心肌病临床试验（ATTR-ACT）和长期扩展研究中，他司美替尼剂量的疗效和安全性。
Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12.
7
Systemic amyloidosis from A (AA) to T (ATTR): a review.系统性淀粉样变，从 A（AA）到 T（ATTR）：综述。
J Intern Med. 2021 Mar;289(3):268-292. doi: 10.1111/joim.13169. Epub 2020 Sep 14.
8
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.硼替佐米、马法兰和地塞米松治疗轻链淀粉样变性。
J Clin Oncol. 2020 Oct 1;38(28):3252-3260. doi: 10.1200/JCO.20.01285. Epub 2020 Jul 30.
9
Left Ventricular Pressure Strain-Derived Myocardial Work at Rest and during Exercise in Patients with Cardiac Amyloidosis.心脏淀粉样变性患者静息和运动时左心室压力应变衍生的心肌作功
J Am Soc Echocardiogr. 2020 Oct;33(10):1295-1296. doi: 10.1016/j.echo.2020.06.001. Epub 2020 Jul 22.
10
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.心肌活检对射血分数保留心力衰竭的特征分析及心脏淀粉样变性的患病率。
JACC Heart Fail. 2020 Sep;8(9):712-724. doi: 10.1016/j.jchf.2020.04.007. Epub 2020 Jul 8.